Rodrigo Estonilo, MD | |
100 Eaglesmere Cir, Suite 200a, East Stroudsburg, PA 18301-3144 | |
(570) 421-8772 | |
(570) 421-8775 |
Full Name | Rodrigo Estonilo |
---|---|
Gender | Male |
Speciality | Pain Medicine - Interventional Pain Medicine |
Location | 100 Eaglesmere Cir, East Stroudsburg, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255342937 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | MD042667L (Pennsylvania) | Primary |
207T00000X | Neurological Surgery | MD042667L (Pennsylvania) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Rodrigo Estonilo, MD 100 Eaglesmere Cir, Suite 200a, East Stroudsburg, PA 18301-3144 Ph: (570) 421-8772 | Rodrigo Estonilo, MD 100 Eaglesmere Cir, Suite 200a, East Stroudsburg, PA 18301-3144 Ph: (570) 421-8772 |
News Archive
Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals Corporation's U.S. Food and Drug Administration Biologics License Application for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram® platform (CAT) from Diagnostica Stago, Inc. (Parsippany, NJ).
Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.
For the first time ever, the World Health Assembly passed a resolution today focused on the prevention and treatment of pneumonia, the world's leading killer of children.
The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostic professionals, today announced that it looks forward to working with the U.S. Food and Drug Administration to determine the best adaptive approach to regulating Next-Generation Sequencing (NGS) tests.
› Verified 6 days ago